?Neurobiology and Brain Tumor Program Brain tumors are the leading cause of cancer-related death in children. Despite rapid advances in our understanding of disease biology, current treatment approaches are still lacking for some patients and lead to long-term, debilitating side effects in others. The goal of the Neurobiology and Brain Tumor Program (NBTP) is to improve survival and morbidity for children with brain tumors by developing effective, relatively non-toxic therapies through a better understanding of disease pathogenesis. The NBTP is an established multidisciplinary Program with a proven record in translating fundamental neuroscience and cancer biology discoveries into novel diagnostics and clinical trials. Our genome-wide studies of the major pediatric brain tumor types identified novel mutations, defined molecular subgroups, and opened new avenues of basic, translational, and clinical investigation. Exciting advances in the fields of molecular pathology, imaging, and radiation oncology provide additional promise for progress in treatment of these clinically formidable diseases. Drs. Suzanne Baker (laboratory lead), an expert in the molecular pathogenesis of brain tumors and Amar Gajjar (clinical lead), a nationally recognized leader in pediatric brain tumor therapeutics are responsible for the leadership of the Program. To facilitate collaboration and drive translation, the NBTP is organized into 3 working groups: Fundamental Neurobiology, Translational Research, and Brain Tumor Therapy. The NBTP has 16 Full Members and 3 Associate (junior mentored) Members, representing the Departments of Bone Marrow Transplantation and Cellular Therapy, Cell and Molecular Biology, Developmental Neurobiology, Genetics, Oncology, Pathology, Pediatric Medicine, Pharmaceutical Sciences, and Radiation Oncology. Program members have a total of $3.8M in annual peer-reviewed funding, including $2.6M in NCI funding, Research from the NBTP has resulted in 458 publications, of which 31.4% are intra-programmatic, 29.9% are inter- programmatic, and 77.5% are inter-institutional (with other NCI-designated Cancer Centers). In addition, during the funding period (2013-2017) the NBTP contributed 879 interventional enrollments of which 762 were therapeutic enrollments. During the current funding period, NBTP accomplishments led to a paradigm shift in the global understanding and treatment of commonly diagnosed pediatric brain tumors. Results from key NBTP studies included an unprecedented view of the somatic mutation landscape of several pediatric brain tumors; novel oncogenic drivers of DIPG and ependymoma; discovery of extensive heterogeneity within virtually all pediatric brain tumor histotypes; and new insights into the cellular origins and pathogenesis of pediatric brain tumors. NBTP members also translated our fundamental genetic discoveries into 4 early-phase clinical trials (SJHG12, SJPDGF, SJDAWN, SJATRT) and the precision medicine phase II trial SJMB12, a randomized, multicenter international study for newly diagnosed medulloblastoma. SJMB12 is the first trial in North America to assign strata based on molecular classification, with therapy translated from NBTP preclinical studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-41
Application #
9883751
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Brinkman, Tara M; Recklitis, Christopher J; Michel, Gisela et al. (2018) Psychological Symptoms, Social Outcomes, Socioeconomic Attainment, and Health Behaviors Among Survivors of Childhood Cancer: Current State of the Literature. J Clin Oncol 36:2190-2197
Fuentes-Alabi, Soad; Bhakta, Nickhill; Vasquez, Roberto Franklin et al. (2018) The cost and cost-effectiveness of childhood cancer treatment in El Salvador, Central America: A report from the Childhood Cancer 2030 Network. Cancer 124:391-397
Wang, Xusheng; Jones, Drew R; Shaw, Timothy I et al. (2018) Target-Decoy-Based False Discovery Rate Estimation for Large-Scale Metabolite Identification. J Proteome Res 17:2328-2334
Sabin, N D; Cheung, Y T; Reddick, W E et al. (2018) The Impact of Persistent Leukoencephalopathy on Brain White Matter Microstructure in Long-Term Survivors of Acute Lymphoblastic Leukemia Treated with Chemotherapy Only. AJNR Am J Neuroradiol 39:1919-1925
Hijano, Diego R; Siefker, David T; Shrestha, Bishwas et al. (2018) Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy. Sci Rep 8:11034
Follis, Ariele Viacava; Llambi, Fabien; Kalkavan, Halime et al. (2018) Regulation of apoptosis by an intrinsically disordered region of Bcl-xL. Nat Chem Biol 14:458-465
Bouchard, Jill J; Otero, Joel H; Scott, Daniel C et al. (2018) Cancer Mutations of the Tumor Suppressor SPOP Disrupt the Formation of Active, Phase-Separated Compartments. Mol Cell 72:19-36.e8
Flerlage, Jamie E; Metzger, Monika L; Bhakta, Nickhill (2018) The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice? Blood 132:376-384
Chen, Wenan; Li, Yan; Easton, John et al. (2018) UMI-count modeling and differential expression analysis for single-cell RNA sequencing. Genome Biol 19:70
Snaman, J M; Talleur, A C; Lu, J et al. (2018) Treatment intensity and symptom burden in hospitalized adolescent and young adult hematopoietic cell transplant recipients at the end of life. Bone Marrow Transplant 53:84-90

Showing the most recent 10 out of 6764 publications